Dosing to efficacy with neurontin: The STEPS trial

Epilepsia

Volumn 40, Issue SUPPL. 6, 1999, Pages s23-s26

  Morrell, Martha J ^a,b  

^a New York Presbyt Epilepsy Center ^*  (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Adjunctive therapy; Efficacy; Epilepsy; Gabapentin; STEPS trial

Indexed keywords

GABAPENTIN;

ADULT; ANTICONVULSANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TITRIMETRY;

EID: 0032870232     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00929.x     Document Type: Conference Paper

References (5)

1. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994;35:795-801.
2. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled parallel-group study. Epilepsia 1993;43:2292-8.
3. UK Gabapentin Study Group. Gabapentin in partial epilepsy: Lancet 1990;335:1114-7.
4. McLean MJ, Morrell MJ, Willmore LJ, et al., and The Neurontin STEPS (Study of Titration to Effect Profile of Safety) Study Group. Safety and tolerability of gabapentin as adjunctive therapy in a large multicenter study. Epilepsia 1999 [in press].
5. Neurontin® (gabapentin capsules). Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Company, 1998: 2110-4.